Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 10.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1999 to 2008

Recipients with Intestine Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 73 82 113 107 116 152 178 175 198 185
Tx with Antirejection Treatments 34 45 41 48 66 59 58 61 57 71
Antibodies Any in Category 47.1% 48.9% 36.6% 31.3% 37.9% 45.8% 39.7% 63.9% 64.9% 56.3%
Atgam/NRATG/NRATS 0.0% 0.0% 2.4% 2.1% 0.0% 3.4% 3.4% 1.6% 3.5% 1.4%
OKT3 44.1% 31.1% 34.1% 27.1% 27.3% 33.9% 22.4% 41.0% 52.6% 26.8%
Thymoglobulin 11.8% 17.8% 7.3% 6.3% 3.0% 13.6% 10.3% 14.8% 12.3% 29.6%
Zenapax 5.9% 6.7% 0.0% 2.1% 1.5% 1.7% 3.4% 3.3% 12.3% 2.8%
Simulect 0.0% 6.7% 0.0% 0.0% 0.0% 0.0% 0.0% 1.6% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 8.3% 15.2% 6.8% 3.4% 8.2% 3.5% 11.3%
Corticosteroids Any in Category 85.3% 75.6% 80.5% 95.8% 92.4% 93.2% 86.2% 82.0% 82.5% 88.7%
Steroids 85.3% 75.6% 80.5% 95.8% 92.4% 93.2% 86.2% 82.0% 82.5% 88.7%
Antimetabolites Any in Category 0.0% 0.0% 2.4% 0.0% 0.0% 0.0% 1.7% 0.0% 0.0% 2.8%
Cytoxan 0.0% 0.0% 2.4% 0.0% 0.0% 0.0% 1.7% 0.0% 0.0% 2.8%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.